Zacks lowered shares of Peregrine Pharmaceuticals (NASDAQ: PPHM) from an outperform rating to a neutral rating in a research report released on Tuesday morning. Zacks currently has $2.30 price target on the stock.
Separately, analysts at Roth Capital upgraded shares of Peregrine Pharmaceuticals from a neutral rating to a buy rating in a research note to investors on Monday, January 7th. They now have a $2.70 price target on the stock.
Shares of Peregrine Pharmaceuticals traded up 8.28% during mid-day trading on Tuesday, hitting $1.83. Peregrine Pharmaceuticals has a one year low of $0.39 and a one year high of $5.50. The stock’s 50-day moving average is currently $1.93. The company’s market cap is $242.5 million.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.